Trial Profile
A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CheckMate 143
- Sponsors Bristol-Myers Squibb
- 13 Sep 2023 Planned End Date changed from 11 Sep 2023 to 8 Apr 2024.
- 13 Jun 2023 Planned End Date changed from 3 Jan 2023 to 11 Sep 2023.
- 16 Nov 2021 Planned End Date changed from 3 Jan 2022 to 3 Jan 2023.